Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study.

ABSTRACT: Rationale: Imatinib, 400 mg daily, reduces pulmonary vascular resistance and improves exercise capacity in patients with pulmonary arterial hypertension. Concerns about safety and tolerability limit its use. Objectives: We sought to identify a safe and tolerated dose of oral imatinib between 100 mg and 400 mg daily and evaluate its efficacy. Methods: Oral imatinib was added to the background therapy of 17 patients with pulmonary arterial hypertension, including 13 who were implanted with devices that provide daily measurements of cardiopulmonary hemodynamics and physical activity. The first patient was started on 100 mg daily. The next 12 patients, recruited serially, were started on 200 mg, 300 mg, or 400 mg daily, following a continuous reassessment dose-finding mode

SUBMITTER: Rothman AMK 

PROVIDER: S-EPMC12175952 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature